Piper reduced Sarepta’s price target to $182 from $200, highlighting the partnership’s near-term financial impact.
The global licensing deal includes $500 million in cash and $325 million in equity, at a 35% premium upon closing.
Arrowhead Research: Fiscal Q3 Earnings Snapshot
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Arrowhead Research: Fiscal Q1 Earnings Snapshot
Arrowhead Research: Fiscal Q3 Earnings Snapshot
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30...
Stocks that traded heavily or had substantial price changes Tuesday: UPS, Packaging Corp. fall, Arrowhead, Tenet rise
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.